1. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study
by Bertrand Godeau, Raphael Porcher, Olivier Fain, François Lefrère, Pierre Fenaux, Stéphane Cheze, Anne Vekhoff, Marie-Paule Chauveheid, Jerôme Stirnemann, Lionel Galicier, Emmanuelle Bourgeois, Stéphanie Haiat, Bruno Varet, Michel Leporrier, Thomas Papo, Mehdi Khellaf, Marc Michel, and Philippe Bierling
Blood
Volume 112(4):
August 15, 2008
©2008 by American Society of Hematology

2. Whisker plots of successive platelet counts of the 24 patients with immune thrombocytopenic purpura whose response to rituximab persisted at week 48.
Whisker plots of successive platelet counts of the 24 patients with immune thrombocytopenic purpura whose response to rituximab persisted at week 48. The central horizontal bold line is the median; the lower and upper box limits are the 1st and 3rd quartiles, respectively; and the whiskers extend to the most extreme data points, which do not exceed 1.5× the interquartile range of the box.
Bertrand Godeau et al. Blood 2008;112:
©2008 by American Society of Hematology

3. One- and 2-year outcomes.
One- and 2-year outcomes. The figures in gray boxes are the numbers of patients in each group in the interim between 1 and 2 years.
Bertrand Godeau et al. Blood 2008;112:
©2008 by American Society of Hematology